Jeito Capital, a global private equity leader in biopharma investment, has announced it is leading a $65 million (EUR 57 million) Series A financing round in ReproNovo, a clinical-stage biopharmaceutical company focused on innovative treatments in reproductive medicine and women’s health.
The funding round, co-led by AXA IM Alts and M Ventures, also saw participation from healthcare-focused investors Ysios Capital and ALSA Ventures. The investment will support the advancement of ReproNovo’s two lead clinical candidates—RPN-001 and RPN-002—both currently in Phase 2 development, targeting critical areas of male infertility and uterine health, respectively.
Advancing Solutions for Global Fertility Challenges
Founded in 2021, ReproNovo aims to bridge unmet needs in fertility and gynecological conditions through pioneering therapies. The company’s leadership team—Chief Executive Officer Jean Marie Duvall, Chief Scientific and Medical Officer Dr. Joan-Carles Arce, and Chief Financial Officer BingMei Hao—bring decades of experience in successful clinical and commercial drug development.
With this fresh capital, ReproNovo plans to accelerate development of:
RPN-001 (leflutrozole): An oral therapy for male infertility caused by low testosterone levels, a growing health issue particularly among younger men. The condition is part of a broader decline in male reproductive health now considered a public health concern.
RPN-002 (nolasiban): A first-in-class oral treatment for adenomyosis, a prevalent and painful gynecological condition involving endometrial tissue growth within the uterus. RPN-002 is also being evaluated for its potential to improve success rates in assisted reproductive technologies (ART).
Recent studies have highlighted the urgency for such innovations, with sperm counts declining by as much as 60% over the past four decades and adenomyosis found in nearly one in four women undergoing gynecological evaluation. These statistics underscore the critical need for new therapeutic approaches across genders in the realm of fertility and reproductive health.
Strategic Vision and Industry Confidence
As part of the investment, Jeito Partner and Chief Commercial Officer Ksenija Pavletic, a veteran in reproductive medicine with 25 years of experience, will join ReproNovo’s Board of Directors.
Dr. Rafaèle Tordjman, Founder and CEO of Jeito Capital, emphasized the societal importance of the investment:
“ReproNovo brings together transformative science, a strong leadership team, and a bold mission to address one of today’s most pressing issues—declining birth rates. We are committed to supporting innovations with the potential to improve lives and shape the future of healthcare.”
Ksenija Pavletic echoed the sentiment, noting:
“With infertility affecting roughly one in six people globally, we are proud to back ReproNovo’s novel therapies. Their scientific depth and proven execution capabilities position them well to tackle unmet needs that have wide-reaching impacts.”
ReproNovo’s CEO, Jean Marie Duvall, described the financing as a pivotal step in the company’s evolution:
“This Series A round marks a significant milestone as we work to become a global leader in reproductive and women’s health. We are grateful for the support from this experienced group of investors who share our vision and commitment.”
About Jeito Capital
Jeito Capital is a global private equity fund dedicated to accelerating high-impact medical innovations. With a focus on patient-centric value creation, Jeito supports biopharmaceutical companies through strategic investment and operational expertise. The firm is headquartered in Paris, with an international footprint across Europe and the United States.
About ReproNovo
ReproNovo is a biopharma company headquartered in Lausanne, Switzerland, with development operations in Copenhagen and Barcelona. Specializing in reproductive medicine and women’s health, the company develops next-generation treatments such as RPN-001 for male infertility and RPN-002 for adenomyosis and embryo implantation. Backed by top-tier investors, ReproNovo is advancing therapies that aim to close persistent treatment gaps in reproductive healthcare.
Related topic:
How Can You Tell If You Have Ovulated?
